{"id":14113,"date":"2011-09-14T12:30:00","date_gmt":"2011-09-14T10:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutici-barclays-declassa-pfizer\/"},"modified":"2011-09-14T12:30:00","modified_gmt":"2011-09-14T10:30:00","slug":"farmaceutici-barclays-declassa-pfizer","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutici-barclays-declassa-pfizer\/","title":{"rendered":"Pharmaceuticals: Barclays downgrades Pfizer"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><font size=\"3\"><strong><em style=\"mso-bidi-font-style: normal\"><span style=\"font-family: 'Verdana','sans-serif'; color: black; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-themecolor: text1\">Barclays<\/span><\/em><\/strong><em style=\"mso-bidi-font-style: normal\"><span style=\"font-family: 'Verdana','sans-serif'; color: black; mso-themecolor: text1\"> today cut its credit rating on <strong><span style=\"font-family: 'Verdana','sans-serif'; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi\">Pfizer<\/span><\/strong> <strong><span style=\"font-family: 'Verdana','sans-serif'; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi\">(US7170811035) <\/span><\/strong>from &quot;Overweight&quot; to &quot;Equal-weight&quot; and the price target at $19. According to the investment bank, the stock of the world leader in the pharmaceutical industry has only limited potential in the short term. Barclays also indicates that Pfizer will face a long-term decline in its core business due to the expiration of the patent coverage of its main products. <\/p>\n<p><\/span><\/em><\/font><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><strong><span style=\"line-height: 115%; font-family: 'Verdana','sans-serif'; color: #006199; font-size: 7.5pt\">Wednesday, September 14, 2011 \u2013&nbsp; <img","protected":false},"excerpt":{"rendered":"<p>Barclays ha tagliato oggi il suo rating su Pfizer (US7170811035) da &quot;Overweight&quot; ad &quot;Equal-weight&quot; ed il target sul prezzo a $19. Secondo la banca d&#8217;affari il titolo del leader mondiale dell&#8217;industria farmaceutica avrebbe nel breve termine solo un limitato potenziale. Barclays indica inoltre che Pfizer dovr&agrave; affrontare nel lungo termine un declino del suo core &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14113","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14113"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14113\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}